Real-World CML drug side effects examined in 2,500 patients

NCT ID NCT07151820

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study analyzed insurance claims from over 2,500 people with chronic myeloid leukemia (CML) to see how often side effects from tyrosine kinase inhibitors (TKIs) occur and how they affect treatment changes and healthcare costs. Researchers looked at side effects that required medical attention. The goal was to understand the real-world burden of these side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tyrosine kinase inhibitors (TKIs)

What this could lead to

If successful, this could help doctors better manage side effects and reduce treatment disruptions for CML patients.

What could go wrong

This is an observational study using insurance claims data, not a controlled trial. It cannot prove cause and effect, and may miss side effects not recorded in claims.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, CHRONIC MYELOID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis

    East Hanover, New Jersey, 07936, United States